<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210515051307N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-11-14</date_registration>
      <primary_sponsor>Skin and Stem cell Research Center of Tehran University</primary_sponsor>
      <public_title>Investigation of the effect of stromal vascular fraction on burn scars</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effectiveness and satisfaction of fractional carbon dioxide laser and stromal vascular fraction in comparison with laser alone in the  treatment of burn scars</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>10</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56337</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, 10 patients with inclusion and exclusion criteria are selected. In each patient by simple randomization method, one burn scar is selected as the intervention group and another scar of the same patient is selected as the control group. For each burn scar, one envelope is randomly selected from two sealed envelopes . The letter a or b is written on each envelope. Envelopes a belong to the intervention group and envelopes b belong to the control group. The patient does not know to which group each envelope is assigned, Blinding description: In this study, the patient is unaware of the type of intervention performed on each burn scar.To blind the patient, a paper cover with the patient's name is attached on the body of the injection syringes .The outcome assessor is a dermatologist who has only images and biometric information of each scar for Vancouer scoring and he does not know the type of intervention.The data analyzer also is a statistician who has only the data to analyze and is not aware of the type of intervention.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Burn scars.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients will receive three sessions of fractional carbon dioxide laser treatment at one-month intervals. Deka fractional carbon dioxide laser device will be used to perform the laser treatment. Its setting will be determined based on the thickness of the scar and the patient's skin type. At the end of the first and third sessions of laser treatment, the Stromal vascular fraction injection will be performed in one of the patients' scars. To prepare it, depending on the required amount and the doctor's diagnosis, between 120 and 200 ccs of fat is drawn from the patient's side or abdomen. Then, after centrifugation and processing, the stromal vascular fraction is isolated. It will be injected into the scar with an insulin syringe. Intervention 2: Control group: Patients will receive three sessions of fractional carbon dioxide laser treatment at one-month intervals. Deka fractional carbon dioxide laser device will be used to perform the laser treatment. Its setting will be determined based on the thickness of the scar and the patient's skin type. At the end of the first and third sessions of laser treatment, in another scar of the patient as the control group, 5cc of the physiological serum will be injected with an insulin syringe.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fariba Khodadad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasoul Akram Hospital,Niayesh St.Sattar Khan St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6655 1719</telephone>
        <email>f.khodadad1991@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fariba Khodadad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasoul Akram Hospital,Niayesh St.Sattar Khan St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6655 1719</telephone>
        <email>f.khodadad1991@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with skin type 1-4
Patients with atrophic burn scars in more than one limb, from five years ago to the last 3 months</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Age under 18 years
Patients who have received laser treatment in the last three months
Patients with active colloidal scar or active skin lesion at the injection site
Patients with coagulation and platelet disorders or a history of taking anticoagulants.
Patients with a history of underlying diseases such as diabetes and autoimmune connective tissue disease that affect the wound healing process
Patients with active viral infections
History of malignancy or receiving chemotherapy
Pregnancy and lactation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L90.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Scar conditions and fibrosis of skin</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients will receive three sessions of fractional carbon dioxide laser treatment at one-month intervals. Deka fractional carbon dioxide laser device will be used to perform the laser treatment. Its setting will be determined based on the thickness of the scar and the patient's skin type. At the end of the first and third sessions of laser treatment, the Stromal vascular fraction injection will be performed in one of the patients' scars. To prepare it, depending on the required amount and the doctor's diagnosis, between 120 and 200 ccs of fat is drawn from the patient's side or abdomen. Then, after centrifugation and processing, the stromal vascular fraction is isolated. It will be injected into the scar with an insulin syringe.</i_keyword>
      <i_keyword>Control group: Patients will receive three sessions of fractional carbon dioxide laser treatment at one-month intervals. Deka fractional carbon dioxide laser device will be used to perform the laser treatment. Its setting will be determined based on the thickness of the scar and the patient's skin type. At the end of the first and third sessions of laser treatment, in another scar of the patient as the control group, 5cc of the physiological serum will be injected with an insulin syringe.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The effectiveness of treatment. Timepoint: Before starting the trial, before the second and third sessions of treatment with laser and two months after the last session. Method of measurement: Photography and biometry of the burn scars will be done. The scoring of the scars will be performed based on the Vancouver scoring system.</prim_outcome>
      <prim_outcome>Patient satisfaction from treatment. Timepoint: Two months after the last session of  treatment with laser. Method of measurement: Patient global assessment score.</prim_outcome>
      <prim_outcome>Physician satisfaction from treatment. Timepoint: Two months after the last session of  treatment with laser. Method of measurement: Physician global assessment score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Iran University of Medical Sciences</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Skin and Stem cell Research Center of Tehran University</source_name>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-05-08</approval_date>
        <contact_name>Ethics Committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Shahid Hemmeat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-11-12</approval_date>
        <contact_name>Ethics Committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Keshavarz Boulevard - Intersection of Ghods Street - Central Building of Tehran University of Medical Sciences Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
